Lupus & antiphospholipid syndrome
Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus
Main finding · Lupus nephritisResult — go to the resultAdjusted hazard ratio 0.55 95% CI 0.40–0.77Authors' conclusion
In this cohort study of patients with SLE and type 2 diabetes, SGLT2i users had a significantly lower risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality than nonusers.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) and type 2 diabetes, US Collaborative Network of TriNetX, 2015–2022 (mean age 56.8 years; 84.8% women)
- Participants
- 3,550 patients1,775 matched pairs
- Exposure
- SGLT2i users vs nonusers
- SGLT2i usersn = 1,775
- Nonusersn = 1,775reference
- Outcome
- Lupus nephritis, dialysis, kidney transplant, HF and mortality (5-year aHRs)
- Follow-up
- 5 years
Methodological detailsmulticenter, 1:1 propensity score matching, Cox proportional hazards regression
- Multicenter
- 1:1 propensity score matching
- Cox proportional hazards regression
Main finding
Lupus nephritis
Adjusted hazard ratio
0.55
95% CI 0.40–0.77
SGLT2i usersvs Nonusers
aHR 0.55 (95% CI 0.40–0.77)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| Dialysis · 5 years | 0.29 (0.17–0.48) | |
| Kidney transplant · 5 years | 0.14 (0.03–0.62) | |
| HF · 5 years | 0.65 (0.53–0.78) | |
| All-cause mortality · 5 years | 0.35 (0.26–0.47) | |
| 0.050.21520Adjusted hazard ratio (log scale) |
Original publication
Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus. JAMA Netw Open. Published 3 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →